Simcere Pharmaceutical Group’s (SCR) MACD indicator has moved into bearish territory with a reading of -0.0220. The Zacks #4 Rank (“Sell”) stock has declined slightly to $7.69 in afternoon trade. The Zacks Consensus Estimate on the company’s full-year earnings has reduced by 11 cents over the past 2 months to 46 cents per share.
“SCR” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Uncategorized